Grifols SA (GRLS.MC)

GRLS.MC on Madrid SE C.A.T.S.

32.76EUR
1 Aug 2013
Price Change (% chg)

€1.04 (+3.30%)
Prev Close
€31.71
Open
€31.97
Day's High
€32.92
Day's Low
€31.91
Volume
500,558
Avg. Vol
637,781
52-wk High
€32.92
52-wk Low
€21.50

GRLS.MC

Chart for GRLS.MC

About

Grifols SA is a Spain-based company engaged in the healthcare sector. The Company is involved in the research, development, manufacturing and marketing of medical solutions for hospitals, which include plasma-derived therapies, as well as diagnosis and pharmaceutical products. Its activities are structured in four segments:... (more)

Overall

Beta: 0.47
Market Cap (Mil.): €9,905.15
Shares Outstanding (Mil.): 343.78
Dividend: 0.20
Yield (%): 0.63

Financials

  GRLS.MC Industry Sector
P/E (TTM): 37.97 37.93 37.76
EPS (TTM): 0.84 -- --
ROI: 5.52 19.48 18.76
ROE: 15.40 20.17 19.59
Search Stocks

Spain's Grifols H1 net profit up 37 pct

MADRID, July 31 - Spanish pharmaceutical company Grifols, the world's third-largest blood products maker, said on Wednesday net profit rose 37 percent in the first half from a year earlier to 182.8 million euros ($242 million), boosted by overseas sales, especially in the United States.

31 Jul 2013

Grifols signs deal to license Aradigm's Pulmaquin

MADRID, May 21 - Spanish drugmaker Grifols said on Tuesday it has signed an exclusive contract to license U.S. Aradigm Corporation's Pulmaquin compound and may take a stake in the California-based firm.

21 May 2013

Spain's Grifols says Q1 net profit up 19 pct y/y

MADRID, May 2 - Spanish pharmaceutical company Grifols said on Thursday net profit rose 19 percent in the first quarter of 2013 from a year earlier to 115.7 million euros ($152.6 million), boosted by overseas sales, especially Latin America and Asia.

02 May 2013

Spain's Grifols reports fivefold increase in 2012 profit

MADRID, Feb 28 - Spanish pharmaceutical company Grifols reported a more than fivefold rise in full-year profit for 2012 to 257 million euros ($336.90 million), buoyed by its acquisition of U.S. firm Talecris last June and its wide geographic presence outside its depressed home market.

28 Feb 2013

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Finlabo SIM Spa
$10.00
Provider: Reuters Investment Profile
$20.00
Provider: Pechala's Reports
$15.00
Provider: Zacks Investment Research Inc.
$12.00
Provider: Zacks Investment Research Inc.
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks